Dr Reddy's Receives 3 USFDA Observations at Srikakulam Facility
Written By : sheeba farhat
Published On 2026-07-30 16:23 GMT | Update On 2026-07-30 16:23 GMT
Advertisement
New Delhi: Dr. Reddy's Laboratories has informed stock exchanges that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 located in Srikakulam, Andhra Pradesh.
According to the company's regulatory filing, the inspection was conducted from July 20 to July 29, 2026. At the conclusion of the inspection, the USFDA issued a Form 483 containing three observations.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.